Promising Role of Reduced-Toxicity Hematopoietic Stem Cell Transplantation (PART-I)

[1]  D. Rondelli,et al.  Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4) , 2011, Bone Marrow Transplantation.

[2]  D. Kaufman,et al.  Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  S. Mackinnon,et al.  Allogeneic transplantation for lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Peggs,et al.  Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation , 2011, Expert opinion on biological therapy.

[5]  M. Scholz,et al.  Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning , 2011, Leukemia.

[6]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Baron,et al.  Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  J. Briones,et al.  Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  B. Dörken,et al.  Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype , 2010, International journal of hematology.

[10]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  S. Pollack,et al.  Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation: A Clinical Review , 2009, American journal of clinical oncology.

[12]  Zhezhen Jin,et al.  Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  R. Larson,et al.  Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence , 2009, Leukemia & lymphoma.

[14]  Brit B. Turnbull,et al.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. , 2009, Blood.

[15]  M. Maris,et al.  Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  S. Lee,et al.  Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study , 2009, Leukemia.

[17]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  D. Weisdorf,et al.  Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma , 2009, Bone Marrow Transplantation.

[19]  R. Fanin,et al.  Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia , 2009, European journal of haematology.

[20]  Larry R. Smith,et al.  Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. , 2008, The Journal of infectious diseases.

[21]  F. Lo‐Coco,et al.  Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy , 2008, Haematologica.

[22]  R. Vij,et al.  Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Blood.

[23]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[24]  C. Craddock.  Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML , 2008, Bone Marrow Transplantation.

[25]  M. Maris,et al.  Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  J. Sierra,et al.  Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Vose,et al.  Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  M. Munsell,et al.  Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience , 2008, Haematologica.

[29]  M. Sorror,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Meisner,et al.  Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. , 2007, Blood.

[31]  D. Douek,et al.  Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. , 2007, Blood.

[32]  J. Storek,et al.  Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  U. Popat,et al.  Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  D. Blaise,et al.  Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. , 2007, Haematologica.

[35]  A. Turner,et al.  Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  A. Nademanee,et al.  Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  M. Maris,et al.  Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  F. Baron,et al.  Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning , 2006, Leukemia.

[39]  N. Mahmud,et al.  Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation , 2006, Bone Marrow Transplantation.

[40]  M. Labopin,et al.  Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[42]  A. Barrett,et al.  Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents , 2006, Leukemia.

[43]  A. Ho,et al.  Highly Efficient Expansion of Human CD4+CD25+ Regulatory T Cells for Cellular Immunotherapy in Patients with Graft-Versus-Host Disease , 2006, Journal of immunotherapy.

[44]  N. Kröger,et al.  Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. , 2006, Experimental hematology.

[45]  C. Flamant,et al.  High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Deeg.  Transplant strategies for patients with myelodysplastic syndromes , 2006, Current opinion in hematology.

[47]  P. Johnson,et al.  Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect , 2006, Bone Marrow Transplantation.

[48]  E. Shpall,et al.  Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[49]  M. Maris,et al.  Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Maris,et al.  Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors , 2006 .

[51]  A. Verdeguer,et al.  Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH) , 2005, Bone Marrow Transplantation.

[52]  T. Sayers,et al.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. , 2005, Blood.

[53]  F. Baron,et al.  Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning , 2005, Current opinion in hematology.

[54]  B. Engels,et al.  Articles on similar topics can be found in the following Blood collections Gene Therapy (517 articles) , 2005 .

[55]  P. Valagussa,et al.  Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  T. Zimmerman,et al.  Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Barrett,et al.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. , 2005, Blood.

[58]  C. Scheibenbogen,et al.  Wilms' tumour gene 1 (WT1) in human neoplasia , 2005, Leukemia.

[59]  A. Ballestrero,et al.  Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer , 2005, The Lancet.

[60]  K. Tobal,et al.  Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia , 2005, Bone Marrow Transplantation.

[61]  J. Radich,et al.  Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  H. Einsele,et al.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.

[63]  S. Heimfeld,et al.  High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation , 2005, Leukemia.

[64]  M. L. Beau,et al.  Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes , 2005, Bone Marrow Transplantation.

[65]  Moo-Song Lee,et al.  Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation , 2005, Annals of Hematology.

[66]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Negrin,et al.  Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. , 2005, Blood.

[68]  S. Heimfeld,et al.  Allogeneic peripheral blood stem cell graft composition affects early T‐cell chimaerism and later clinical outcomes after non‐myeloablative conditioning , 2005, British journal of haematology.

[69]  X. Thomas,et al.  Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced‐intensity conditioning regimens , 2005, British journal of haematology.

[70]  S. Mackinnon,et al.  Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[71]  A. Bacigalupo.  Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects , 2005, Bone Marrow Transplantation.

[72]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[73]  R. Storb,et al.  Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease , 2005, Current opinion in hematology.

[74]  H. Nieuwenhuis,et al.  Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation , 2004, Transplant infectious disease : an official journal of the Transplantation Society.

[75]  M. Maris,et al.  Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. , 2004, Blood.

[76]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning , 2004 .

[77]  D. Olive,et al.  CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. , 2004, Experimental hematology.

[78]  J. Radich,et al.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.

[79]  N. Kröger,et al.  Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[80]  S. Mineishi,et al.  Graft-versus-Host Disease in Mini-transplant , 2004, Leukemia & lymphoma.

[81]  J. Gribben,et al.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.

[82]  G. Mufti,et al.  Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. , 2004, Blood.

[83]  C. Flowers,et al.  Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.

[84]  H. Tamaki,et al.  WT1 Gene Transcript Assay for Relapse in Acute Leukemia after Transplantation , 2004, Leukemia & lymphoma.

[85]  R. Brand,et al.  BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning , 2004, Leukemia.

[86]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[87]  M. Munsell,et al.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[88]  R. Truitt.  The Mortimer M. Bortin Lecture: to destroy by the reaction of immunity: the search for separation of graft-versus-leukemia and graft-versus-host. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[89]  E. Kjeldsen,et al.  WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study , 2004, British journal of haematology.

[90]  D. Cilloni,et al.  WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic Syndrome , 2004, Acta Haematologica.

[91]  N. Geller,et al.  Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. , 2004, Blood.

[92]  A. Bacigalupo.  Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus , 2004, Bone Marrow Transplantation.

[93]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[94]  M. Maris,et al.  Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. , 2004, Blood.

[95]  G. Mufti,et al.  BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. , 2004, Blood.

[96]  D. Blaise,et al.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. , 2004, Blood.

[97]  P. Mclaughlin,et al.  Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  G. Hortobagyi,et al.  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. , 2003, Blood.

[99]  E. Estey,et al.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. , 2003, Blood.

[100]  D. Blaise,et al.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.

[101]  W. Siegert,et al.  Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor , 2003, Bone Marrow Transplantation.

[102]  R. Brand,et al.  Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning , 2003, Leukemia.

[103]  S. Saidman,et al.  Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[104]  S. Mineishi,et al.  Impact of graft‐versus‐host disease in reduced‐intensity stem cell transplantation (RIST) for patients with haematological malignancies , 2003, British journal of haematology.

[105]  N. Hosen,et al.  The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. , 2003, Blood.

[106]  A. Nagler,et al.  Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. , 2003, Blood.

[107]  A. Ho,et al.  Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease , 2002, Leukemia.

[108]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[109]  R. Storb.  Mixed allogeneic chimerism and graft-versus-leukemia effects in acute myeloid leukemia , 2002, Leukemia.

[110]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[111]  P. Mclaughlin,et al.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.

[112]  H. Deeg,et al.  Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation , 2001, British journal of haematology.

[113]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[114]  R. Storb.  Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia? , 2001, Leukemia.

[115]  M. Remberger,et al.  T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. , 2001, Transplantation.

[116]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[117]  N. Ueno,et al.  Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. , 2000, British journal of haematology.

[118]  G. Hill,et al.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.

[119]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[120]  R. Storb,et al.  Mixed chimerism: preclinical studies and clinical applications. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[121]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[122]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[123]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  M. Martelli,et al.  Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. , 1996, Transplantation proceedings.

[125]  H. Deeg,et al.  Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. , 1996, Bone marrow transplantation.

[126]  J. Wingard,et al.  Association of busulfan area under the curve with veno-occlusive disease following BMT. , 1996, Bone marrow transplantation.

[127]  L. Barnett,et al.  Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.

[128]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[129]  Z. Karabekian,et al.  Stem Cell Rev and Rep , 2010 .

[130]  M. Sorror,et al.  Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. , 2008, Blood.

[131]  A. Gratwohl,et al.  Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors , 2007, Bone Marrow Transplantation.

[132]  J. Finke,et al.  Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning – is there still an upper age limit? A focus on myeloid neoplasia , 2007, Leukemia.

[133]  A. Nagler,et al.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.

[134]  N. Schmitz,et al.  Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. , 2005, Haematologica.

[135]  A. Venditti,et al.  Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. , 2004, The hematology journal : the official journal of the European Haematology Association.

[136]  P. Musto,et al.  A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity. , 2004, Haematologica.

[137]  N. Kröger,et al.  Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma , 2004, Leukemia.

[138]  J. Sierra,et al.  Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. , 2003, Haematologica.

[139]  J. A. Castillejo,et al.  Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. , 2003, Haematologica.

[140]  J. Hancock,et al.  Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR , 2003, Leukemia.

[141]  A. Pileri,et al.  Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. , 2002, Blood.

[142]  R. Storb,et al.  Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. , 1986, Blood.